白蛋白结合型紫杉醇联合卡铂在铂类敏感复发性卵巢癌患者中的临床观察  

Clinical Observation of Albumin-binding Paclitaxel Combined with Carboplatin in Patients with Platinum-sensitive Recurrent Ovarian Cancer

作　　者：王崇[1] 陆林[1] 高世乐 Wang Chong;Lu Lin;Gao Shile(Department of the First Tumor Section,The 901st Hospital of the PLA Joint Logistics Support Force Primary the 105th Hospital of PLA,Anhui 230031,China;不详)

机构地区：[1]中国人民解放军联勤保障部队第901医院(原解放军第105医院)肿瘤一科,合肥230031 [2]中国人民解放军联勤保障部队第901医院(原解放军第105医院)肿瘤四科,合肥230031

出　　处：《医学研究杂志》2019年第11期153-157,共5页Journal of Medical Research

摘　　要：目的观察白蛋白结合型紫杉醇联合卡铂在铂类敏感复发性卵巢癌患者中的疗效和不良反应.方法选取笔者医院2014年1月1日~2016年1月1日收治的60例铂类敏感复发性卵巢癌患者作为研究对象,按照数字表法随机分为对照组28例和治疗组32例.对照组给予吉西他滨联合卡铂方案化疗,治疗组给予白蛋白结合型紫杉醇联合卡铂方案化疗,3周为1个化疗周期,共化疗4个周期.化疗结束后1个月比较两组患者KPS评分、肿瘤标志物CEA、CA125变化,按照RECIST1.1评价CR、PR、SD、PD和ORR、DCR以及不良反应情况.结果两组患者治疗后生活质量较治疗前有所提高,治疗组患者KPS评分稍高于对照组,但两组间KPS比较差异无统计学意义(P>0.05),治疗组患者血清CEA及CA125低于对照组患者(P<0.05).对照组患者CR、PR、SD、PD和ORR、DCR分别为2、13、9、4例和53.6%、85.7%,治疗组患者CR、PR、SD、PD和ORR、DCR分别为6、19、5、2例和78.1%、93.8%;治疗组患者ORR显著高于对照组(P<0.01),DCR高于对照组(P<0.05).两组患者主要不良反应为骨髓抑制、恶心、呕吐、腹泻,在骨髓抑制、恶心、呕吐方面差异无统计学意义(P>0.05),治疗组患者腹泻发生率高于对照组(P<0.05),经对症处理后均缓解,未发生严重致死病例.结论二线治疗是决定铂类敏感复发性卵巢癌患者预后的重要因素,白蛋白结合型紫杉醇联合卡铂方案化疗在铂类敏感复发性卵巢癌中疗效确切,不良反应可控,为铂类敏感复发性卵巢癌患者提供新的治疗途径,值得临床推广.Objective To observe the efficacy and side effects of albumin-binding paclitaxel combined with carboplatin in platinum-sensitive recurrent ovarian cancer patients.Methods Sixty patients with platinum-sensitive recurrent ovarian cancer admitted to our hospital from January 1,2014 to January 1,2016 were selected as subjects.According to the digital grouping method,they were randomly divided into 28 cases in the control group and 32 cases in the treatment group.The control group was given gemcitabine combined with carboplatin regimen chemotherapy,while the treatment group was given albumin-bound paclitaxel combined with carboplatin regimen chemotherapy,with three weeks as a chemotherapy cycle,a total of four cycles of chemotherapy.After one month,KPS score,CEA and CA125 were compared between the two groups the end of chemotherapy.CR,PR,SD,PD,ORR,DCR and adverse reactions were evaluated according to RECIST 1.1.Results After treatment,the quality of life of the two groups was improved.The KPS score of the treatment group was slightly higher than that of the control group.There was no significant difference in KPS between the two groups(P>0.05).The serum CEA and CA125 of the treatment group were lower than the control group(P<0.05).CR,PR,SD,PD,ORR and DCR were 2,13,9,4 and 53.6% and 85.7% in the control group,while CR,PR,SD,PD,ORR and DCR in the treatment group were 6,19,5,2 and 78.1% and 93.8% respectively.ORR in the treatment group was significantly higher than that in the control group(P<0.01),and DCR was higher than that in the control group(P<0.05).The main adverse reactions of the two groups were bone marrow suppression,nausea,vomiting and diarrhea.There was no significant difference in bone marrow suppression and nausea and vomiting between the two groups(P>0.05).The incidence of diarrhea in the treatment group was higher than that in the control group(P<0.05).Conclusion Second-line treatment is an important factor to determine the prognosis of patients with platinum-sensitive recurrent ovarian cancer.Albumin-bo

关 键 词：白蛋白结合型紫杉醇 卡铂 吉西他滨 铂类敏感 复发性 卵巢癌 

分 类 号：R737[医药卫生—肿瘤]